LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 4 6 8
ROE
(17.63%) (19.24%) 9.54% 15.40%
ROA
(8.56%) (9.49%) 4.22% 7.33%
ROIC
12.81% 13.24% 12.52% 10.63%
Return on Tangible Assets
(44.56%) (45.22%) 21.12% 31.88%
Average Days of Receivables
57.25 56.80 58.38 57.37
Free Cash Flow per Share
3.51 3.31 3.08 2.83
Free Cash Flow
191.52 180.57 168.32 155.59
Capital Expenditures
(59.13) (73.77) (77.27) (93.67)
Other line items
Cash ROIC
8.56% 8.16% 8.26% 7.29%
Accounts Receivable Turnover
6.60 6.79 6.65 6.52
Accounts Payable Turnover
5.28 5.37 4.99 4.93
Inventory Turnover
2.66 2.87 2.92 2.78
Average Days of Payables
73.35 79.12 77.64 80.38
Days of Inventory on Hand
139.40 134.13 129.61 134.20
Tax Rate
0.13 0.10 (0.12) 0.76
Research and Development Expense of Revenue
13.12% 13.38% 14.41% 14.48%
Selling, General and Administrative Expense of Revenue
39.43% 39.54% 39.29% 39.66%
Share Based Compensation of Revenue
2.51% 2.61% 2.57% 3.02%
Interest Coverage
3.41 4.05 4.55 5.43
Operating CF/Net income
(1.15) (1.05) 2.29 1.32
Depreciation/Fixed assets
0.37 0.34 0.32 0.31
Capex/Depreciation
(0.73) (0.89) (0.93) (1.10)
Revenue per Share
24.69 25.45 26.21 26.77
Operating CF per Share
4.59 4.66 4.49 4.53
Capex per Share
(1.08) (1.35) (1.41) (1.70)
Capex to Sales
0.04 0.05 0.05 0.06

Fold the line items

Columns are period end dates